Table 2.
Risk estimates for confirmed intussusception cases after Rotarix®/RotaTeq® vaccination, vaccinees-only SCCS approach
| Vaccine dose | Risk period(days post-vaccination) | Number of cases | Non-risk period(days post-vaccination) | Number of cases | IRR (95% CI)(crude) | IRR (95% CI)(age-adjusted) |
|---|---|---|---|---|---|---|
| Dose 1 | ||||||
| 1–7 | 3 | 22–42 | 1 | 9.0 (0.9–86.5) | 4.7 (0.3–74.1) | |
| 8–21 | 1 | 1.5 (0.1–24.0) | 0.8 (0.1–13.9) | |||
| Dose 2 | ||||||
| 1–7 | 1 | 22–42 | 2 | 1.5 (0.1–16.5) | 1.6 (0.1–32.3) | |
| 8–21 | 3 | 2.3 (0.4–13.5) | 3.9 (0.3–44.0) | |||
| Dose 3 | ||||||
| 1–7 | 0 | 22–42 | 1 | 3.0 (0.2–48.0) | Non interpretable1 | |
| 8–21 | 0 | Non interpretable1 | Non interpretable1 |
*
The observation period for each vaccine dose ends at day 42 post-vaccination.
1
Non-interpretable IRR due to very small numbers.
Abbreviations: Intussusception (IS); Confidence interval (CI).